Schechter Investment Advisors LLC Lowers Stock Holdings in Grifols, S.A. (NASDAQ:GRFS)

Schechter Investment Advisors LLC trimmed its position in Grifols, S.A. (NASDAQ:GRFS) by 25.2% during the fourth quarter, HoldingsChannel reports. The institutional investor owned 90,044 shares of the biotechnology company’s stock after selling 30,358 shares during the period. Schechter Investment Advisors LLC’s holdings in Grifols were worth $670,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. Whitebox Advisors LLC lifted its holdings in shares of Grifols by 56.2% in the third quarter. Whitebox Advisors LLC now owns 4,221,483 shares of the biotechnology company’s stock worth $37,487,000 after buying an additional 1,519,093 shares in the last quarter. JPMorgan Chase & Co. increased its position in shares of Grifols by 144.0% in the third quarter. JPMorgan Chase & Co. now owns 2,002,511 shares of the biotechnology company’s stock worth $17,782,000 after purchasing an additional 1,181,959 shares during the last quarter. Anthracite Investment Company Inc. bought a new position in shares of Grifols in the third quarter worth approximately $5,457,000. Barclays PLC increased its position in shares of Grifols by 381.2% in the third quarter. Barclays PLC now owns 592,552 shares of the biotechnology company’s stock worth $5,261,000 after purchasing an additional 469,401 shares during the last quarter. Finally, Verition Fund Management LLC bought a new position in shares of Grifols in the third quarter worth approximately $2,636,000.

Grifols Stock Down 3.6 %

GRFS stock opened at $8.27 on Wednesday. The company has a current ratio of 2.26, a quick ratio of 0.79 and a debt-to-equity ratio of 1.11. The company’s 50 day moving average is $7.43 and its 200 day moving average is $8.14. The stock has a market cap of $5.69 billion, a price-to-earnings ratio of 7.07 and a beta of 0.40. Grifols, S.A. has a 1-year low of $5.30 and a 1-year high of $9.96.

Wall Street Analyst Weigh In

Separately, Morgan Stanley assumed coverage on shares of Grifols in a research report on Wednesday, February 12th. They issued an “overweight” rating on the stock.

Grifols Company Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.